Compulsory Licensing of Patents: the Bayer-Natco Case

Bonadio, E. (2012). Compulsory Licensing of Patents: the Bayer-Natco Case. European Intellectual Property Review, 34(10), pp. 719-728.

[img]
Preview
PDF - Accepted Version
Download (255kB) | Preview

Abstract

On 9th March 2012 the Indian Controller of Patents granted the first compulsory licence in India. Indian generics producer Natco Pharma Ltd. has been granted the right to produce and sell in India Bayer’s patented medicine “Sorafenib”, which is useful for treating advanced stage liver and kidney cancer.

After a brief introduction on cumpulsory licences under the TRIPS Agreement and the Paris Convention, the author verifies whether the decision of the Controller of Patents satisfies the conditions set forth by the these international treaties in relation to compulsory licences. He concludes inter alia that the ruling might be in violation of the non discrimination principle enshrined in Article 27(1) TRIPS.

General comments are also made about the role of compulsory licensing in guaranteeing the availability of patented products to a wide range of consumers and in general the transfer and dissemination of the associated technology.

Item Type: Article
Subjects: K Law > K Law (General)
Divisions: The City Law School
URI: http://openaccess.city.ac.uk/id/eprint/4101

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics